AI Stock Memo: IRMD - IRadimed - RankAlpha

IRMD

AI Memo

IRadimed

As of 2026-01-19/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-19 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Hospital procurement / contract announcements • 2027-01-19

Expected move: +7%

Biggest risk

Hospital purchasing remains weak, reimbursement or pricing pressure intensifies, or competition erodes market share, stalling revenue growth. A concentrated product mix and margin compression lead to multiple contraction and push the stock toward the bear target.

Invalidation

Break below $75 or thesis failure.

What would change my mind?

IRadimed achieves accelerated hospital adoption and wins multiple contracts, expanding recurring consumables revenue and improving scale economics. Positive clinical or regulatory outcomes broaden the addressable market and support meaningful multiple expansion toward the bull target.

Research note

Recommendation

—

Confidence

medium

As of

2026-01-19

Base target

$99

p=60%

Bull target

$130

p=20%

Bear target

$75

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Quarterly earnings / guidance refresh
Regulatory/clinical adoption milestone
IRadimed achieves accelerated hospital adoption and wins multiple contracts, expanding recurring consumables revenue and improving scale economics.

BearKey bullets

Adverse reimbursement or regulatory rulings
Concentration in few product lines/customers
Slow hospital procurement cycles

WatchKey bullets

Hospital procurement / contract announcements

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $99 (p=60%)

Bull/Bear spread: +41% / -19%

Vs latest close: Bull +41% · Base +7% · Bear -19%

Scenario probabilities

Bull Target: $130 (p=20%)Base Target: $99 (p=60%)Bear Target: $75 (p=20%)

Commentary

Consensus targets cluster near $98–$100, signaling mixed-to-neutral expectations with the median below the anchor [#SERP-4]. Short-term sentiment will hinge on earnings and contract news; concentrated ownership and target revisions can amplify moves [#SERP-1].

As of 2026-01-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Quarterly earnings / guidance refresh
Regulatory/clinical adoption milestone

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-19Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$98.49

Range (USD)

$72.00 - $105.00

Count

Query: IRadimed Corp Common (IRMD) analyst consensus price target high low average

Iradimed Corp (IRMD) Stock Forecast, Price Targets and ... - TipRanks
Search result #1
The highest analyst price target is $100.00 ,the lowest forecast is $98.00. The average price target represents 29.55% Increase from the current price of $76. ...
Extracted: $100.00, $98.00, $76.00Open source
IRADIMED CORP (IRMD) Stock Analyst Ratings - ChartMill.com
Search result #2
8 analysts have analysed IRMD and the average price target is 74.97 USD. This implies a price decrease of -4.46% is expected in the next year compared to the ...
Extracted: $74.97Open source
Iradimed Co Consensus Estimates (IRMD) - Investing.com NG
Search result #3
According to projections from 2 analysts, the average 12-month price target for Iradimed Co is 99, with a high estimate of 100 and a low estimate of 98. What Is ...
Open source
IRADIMED CORPORATION: Target Price Consensus and Analysts ...
Search result #4
Analysts' Consensus ; Last Close Price. 95.50USD ; Average target price. 99.00USD ; Spread / Average Target. +3.66% ; High Price Target. 100.00USD ; Spread / Highest ...
Extracted: $95.50, $99.00, $100.00Open source
What is the current Price Target and Forecast for iRadimed (IRMD)
Search result #5
The forecasts range from a low of $98.00 to a high of $100.00. The average price target represents a decline of 3.48% from the last closing price of $102.57.
Extracted: $98.00, $100.00, $102.57Open source
IRADIMED CORPORATION (IRMD) Analyst Ratings, Estimates ...
Search result #6
See IRADIMED CORPORATION (IRMD) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.
Open source

Scenarios

Bull Target (Scenario probability)

$130 / p=20% prob

Base Target (Scenario probability)

$99 / p=60% prob

Bear Target (Scenario probability)

$75 / p=20% prob

Price $92 as of 2026-06-18

Nearest Scenario: Base (∆ 7%)

Targets vs latest close: Bull +41% · Base +7% · Bear -19%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2027-01-19
Hospital procurement / contract announcements
New purchasing wins or broadened OR/MRI-suite adoption would materially lift revenue run-rate; timing tied to multi-quarter procurement cycles so use one-year horizon [#SERP-4].
Prob 30.00% • Move 30.00% • Priced-in 15.00%

Short-term Catalysts

Next few weeks

Quarterly earnings / guidance refresh
2026-04-19
Upcoming FY2025/Q4 results and any guidance revision could move price; no firm release date disclosed so conservatively set to 90 days out [#SERP-6].
Prob 65% • Move 12% • Priced-in 40%

Long-term Catalysts

Months to a year

Regulatory/clinical adoption milestone
2027-01-19
Clinical study results or regulatory clarity that expands addressable market could trigger larger re-rating; assumed one-year horizon absent public timetable [#SERP-8].
Prob 25% • Move 40% • Priced-in 10%

Risks

Adverse reimbursement or regulatory rulings
Concentration in few product lines/customers
Slow hospital procurement cycles

Peers

Symbol	Summary
ICUI	Direct infusion and monitoring peer with similar hospital sales cycles; useful commercial comparator.
BDX	Large med‑tech OEM; comparable on distribution, regulatory oversight, and scale advantages.
BAX	Global hospital supplier with infusion exposure; relevant for procurement and reimbursement dynamics.
TFX	Procedural-device company with recurring revenue characteristics and hospital channel exposure.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: IRadimed Corp Common (IRMD) analyst consensus price target high low average
Analysis date: 2026-01-19